Clinical trials: Docetaxel, completed
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
This randomized parallel group study will assess the efficacy and safety of erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or…
- Trial name
- NCT01204697
- Testing
- docetaxel, erlotinib [Tarceva]
- Where
- 20 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
The Synergism Or Long Duration (SOLD) Study
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent…
- Trial name
- SOLD (NCT00593697)
- Testing
- trastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
- Where
- Finland
- Volunteers
- 2,168 people
- Sponsor
- Finnish Breast Cancer Group
Non-small Cell Lung Cancer
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
To assess the antitumour activity (response rate) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and gemcitabine and of a sequential treatment of…
- Trial name
- NCT00425191
- Testing
- Docetaxel and Gemcitabine, Gemcitabine cisplatin followed by docetaxel
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Sanofi
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00016185
- Testing
- alvocidib, docetaxel
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
Primary Objective 1. To develop a pharmacokinetic-pharmacodynamic (PD) model for optimisation of docetaxel dosing Secondary Objectives 1. To establish an exposure-toxicity (neutropenia) relationship for docetaxel 2.
- Trial name
- NCT00703378
- Testing
- Docetaxel (Taxotere®)
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00046826
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Nuvance Health
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received…
- Trial name
- NCT03834506
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 215 sites in United States, Argentina and 19 more
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer
- Trial name
- NCT00214058
- Testing
- Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
Neoplasms
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)
- Trial name
- NCT02171676
- Testing
- Docetaxel, BIBW 2992
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.
- Trial name
- NCT00705315
- Testing
- Docetaxel, Epirubicin, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
- Trial name
- ENSPIRIT (NCT01630733)
- Testing
- Custirsen, Docetaxel
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 664 people
- Sponsor
- Achieve Life Sciences
Lung Cancer
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT01207011
- Testing
- Amrubicin hydrocloride, Docetaxel
- Where
- Japan
- Volunteers
- 202 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Breast Cancer
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
The combination of docetaxel+epirubicin is highly effective and well tolerated as first line treatment in patients with metastatic breast cancer (MBC).
- Trial name
- NCT00429871
- Testing
- Docetaxel, Capecitabine, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 272 people
- Sponsor
- Hellenic Oncology Research Group
Prostate Cancer
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy.
- Trial name
- NCT00136526
- Testing
- Docetaxel and Diethylstilbestrol (DES)
- Volunteers
- 30 people
- Sponsor
- University of Washington
Prostate Cancer
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II…
- Trial name
- NCT00115635
- Testing
- docetaxel, gemcitabine
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Herlev Hospital
Urothelial Carcinoma
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
- Trial name
- RANGE (NCT02426125)
- Testing
- Ramucirumab, Docetaxel
- Where
- 141 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Squamous Cell
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To assess the response rate to induction therapy with docetaxel/CDDP. Secondary objectives: To assess Resectability after induction therapy Time to progression Overall survival Safety profile Quality of Life
- Trial name
- NCT00432315
- Testing
- Docetaxel + CDDP
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.